Metrics Contract Services Expands Staff with New Senior Formulation Scientist
Michael R. Mascarenas provides clients with quality formulation and process development of early-phase oral dosage forms.
Greenville, NC, July 15, 2015 --(PR.com)-- Metrics Contract Services (Metrics) has added a new senior formulation scientist to its growing staff of pharmaceutical experts.
Among his other duties, Michael R. Mascarenas is responsible for the formulation and process development of early-phase oral dosage forms, and oversees the manufacture of clinical trial materials to support client-sponsored research studies.
Before joining Metrics, Mascarenas worked as a principal process expert with Sandoz, where he planned and executed engineering, scale up, abbreviated new drug application and registration batches, and in-sourced DEA schedule products. Prior to that, he worked as a formulation scientist with Glatt Air Techniques. Mascarenas’ areas of expertise include Lean Six Sigma methodologies and Quality by Design principles.
Joining Metrics represents a homecoming for Mascarenas, who worked as a development scientist and analytical scientist at the company from 2004 through 2006. He holds a bachelor’s of science degree in biology from East Carolina University.
Formulation development scientists at Metrics bring, on average, 17 years of career experience to their roles. The team has successfully produced clinical trial materials for 140 first-time-in-man, fast-track studies, and routinely commits to a 16- to 24-week timeline from receipt of a well-characterized new chemical entity to shipment.
About Metrics Contract Services
Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms.
Our areas of expertise include quality formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing. Our technical capabilities include highly potent, cytotoxic and unstable compounds; DEA Schedule II-V controlled substances; and products with poor bioavailability, for which we offer an impressive propriety portfolio of advanced delivery methods. Located in Greenville, N.C., Metrics Contract Services is a proud member of the Mayne Pharma family. Learn more online.
About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange. The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.
Among his other duties, Michael R. Mascarenas is responsible for the formulation and process development of early-phase oral dosage forms, and oversees the manufacture of clinical trial materials to support client-sponsored research studies.
Before joining Metrics, Mascarenas worked as a principal process expert with Sandoz, where he planned and executed engineering, scale up, abbreviated new drug application and registration batches, and in-sourced DEA schedule products. Prior to that, he worked as a formulation scientist with Glatt Air Techniques. Mascarenas’ areas of expertise include Lean Six Sigma methodologies and Quality by Design principles.
Joining Metrics represents a homecoming for Mascarenas, who worked as a development scientist and analytical scientist at the company from 2004 through 2006. He holds a bachelor’s of science degree in biology from East Carolina University.
Formulation development scientists at Metrics bring, on average, 17 years of career experience to their roles. The team has successfully produced clinical trial materials for 140 first-time-in-man, fast-track studies, and routinely commits to a 16- to 24-week timeline from receipt of a well-characterized new chemical entity to shipment.
About Metrics Contract Services
Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms.
Our areas of expertise include quality formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing. Our technical capabilities include highly potent, cytotoxic and unstable compounds; DEA Schedule II-V controlled substances; and products with poor bioavailability, for which we offer an impressive propriety portfolio of advanced delivery methods. Located in Greenville, N.C., Metrics Contract Services is a proud member of the Mayne Pharma family. Learn more online.
About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange. The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.
Contact
Metrics, Inc.
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Contact
Categories